Renee Wilson [3]Renee M. Wilson [1]
  1.  44
    An Approach to Evaluating Therapeutic Misconception.Scott Y. H. Kim, Lauren Schrock, Renee M. Wilson, Samuel A. Frank, Robert G. Holloway, Karl Kieburtz & Raymond G. De Vries - 2009 - IRB: Ethics & Human Research 31 (5):7.
    Subjects enrolled in studies testing high risk interventions for incurable or progressive brain diseases may be vulnerable to deficiencies in informed consent, such as the therapeutic misconception. However, the definition and measurement of the therapeutic misconception is a subject of continuing debate. Our qualitative pilot study of persons enrolled in a phase I trial of gene transfer for Parkinson disease suggests potential avenues for both measuring and preventing the therapeutic misconception. Building on earlier literature on the topic, we developed and (...)
    Direct download (2 more)  
    Export citation  
    Bookmark   15 citations  
  2.  45
    Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?Scott Y. H. Kim, Raymond De Vries, Sonali Parnami, Renee Wilson, H. Myra Kim, Samuel Frank, Robert G. Holloway & Karl Kieburtz - 2015 - Journal of Medical Ethics 41 (5):391-397.
    Direct download (6 more)  
    Export citation  
    Bookmark   9 citations  
  3.  35
    Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?Scott Y. H. Kim, Renee Wilson, Raymond De Vries, Kerry A. Ryan, Robert G. Holloway & Karl Kieburtz - 2016 - Journal of Medical Ethics 42 (8):514-518.
    Direct download (3 more)  
    Export citation  
    Bookmark   5 citations  
  4.  34
    Trust in early phase research: therapeutic optimism and protective pessimism.Scott Y. H. Kim, Robert G. Holloway, Samuel Frank, Renee Wilson & Karl Kieburtz - 2008 - Medicine, Health Care and Philosophy 11 (4):393-401.
    Bioethicists have long been concerned that seriously ill patients entering early phase (‘phase I’) treatment trials are motivated by therapeutic benefit even though the likelihood of benefit is low. In spite of these concerns, consent forms for phase I studies involving seriously ill patients generally employ indeterminate benefit statements rather than unambiguous statements of unlikely benefit. This seeming mismatch between attitudes and actions suggests a need to better understand research ethics committee members’ attitudes toward communication of potential benefits and risks (...)
    Direct download (3 more)  
    Export citation  
    Bookmark   6 citations